Intensified immunosuppressive therapy (IIST) in patients with immune checkpoint inhibitor-induced myocarditis

Authors
Jennifer Cautela, Sarah Zeriouh, Melanie Gaubert, Laurent Bonello, Marc Laine, Michael Peyrol, Franck Paganelli, Nathalie Lalevee, Fabrice Barlesi, Franck Thuny

Correspondence
franck.thuny@gmail.com from The Mediterranean University Centre of Cardio-Oncology, Aix Marseille University, France

In Brief
The need for IIST was more common in patients who developed immune checkpoint inhibitor-induced (ICI) myocarditis very early after the start of ICI therapy, as well as when hemodynamic/electrical instability or neuromuscular adverse events occurred. Treatment with infliximab might be associated with an increased risk of cardiovascular death.